US2006199268A1PendingUtilityA1
Method for assessing arteriosclerosis and diabetic nephropathy
Est. expiryMar 7, 2025(expired)· nominal 20-yr term from priority
G01N 33/942G01N 2800/042Y10T436/145555G01N 2800/323G01N 2800/347
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is.
Claims
exact text as granted — not AI-modified1 . A method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is.
2 . A method for assessing diabetic nephropathy comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the diabetic nephropathy is.
3 . The method according to claim 2 , which comprises:
a) measuring the whole blood, serum or platelet-rich plasma serotonin level in an individual; b) measuring the whole blood, serum or platelet-rich plasma serotonin level in a healthy individual; and c) rating the whole blood, serum or platelet-rich plasma serotonin level obtained in a) on such a scale that the more it exceeds the corresponding serotonin level in the healthy individual obtained in b), the more serious the diabetic nephropathy is.
4 . A method for assessing diabetic nephropathy comprising measuring the serotonin level in platelet-poor plasma and rating the serotonin level on such a scale that the higher it is, the more serious the nephropathy is.
5 . A method for assessing diabetic nephropathy comprising:
a) measuring the whole blood, serum or platelet-rich plasma serotonin level in an individual; b) measuring the platelet-poor plasma serotonin level in the same individual; and c) rating the ratio of the platelet-poor plasma serotonin level obtained in b) to the whole blood, serum or platelet-rich plasma serotonin level obtained in a) on such a scale that the higher the ratio is, the more serious the diabetic nephropathy.Join the waitlist — get patent alerts
Track US2006199268A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.